Navigation Links
Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit
Date:1/28/2008

RALEIGH, N.C., Jan. 28 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotechnology industries, today announced that Nader Naeymi-Rad, Senior Vice President of the firm's Brand Management practice, will speak at the EyeForPharma Oncology Summit Europe. The event will be held on January 30-31, 2008, at the Regent's Park Marriott Hotel in London, England.

Mr. Naeymi-Rad's presentation, titled "Key Success Factors for Launching Oncology Products in Europe," is slated for 2:00 pm on January 30 and will cover:

-- The unique characteristics of the oncology market and how they affect a

product launch

-- The nuances of launching products in Europe versus other regions of the

world

-- How best to manage the logistics of a product launch

"Launching a new pharmaceutical product is a complex and challenging undertaking. It becomes significantly more so when that product is an oncologic. The oncology market is complicated and becoming ever more competitive, the products themselves are complex, and launch managers face a wide range of strategic and operational challenges that are not often apparent when launching more traditional drugs in a primary care environment," stated Mr. Naeymi-Rad.

As the head of Campbell Alliance's Brand Management Practice, Mr. Naeymi- Rad is an expert at developing and implementing commercial strategies and improving commercial processes.

For more information on the EyeForPharma Oncology Summit Europe, please visit http://www.eyeforpharma.com/oncology08 .

Executives from Campbell Alliance speak at many conferences in the US and Europe each year. For a full listing of events, please refer to the company's online conference calendar at http://www.campbellalliance.com/pressroom/eventcalendar.cfm .

About the Brand Management Practice at Campbell Alliance

The Brand Management practice at Campbell Alliance can help enhance the commercial performance of products from initial launch through product maturity. The firm's team members are experts at new product planning, commercial strategy development, brand planning, product launch, and myriad other aspects of maximizing the value of pharmaceutical assets. The team has also developed commercial strategies and programs in numerous geographic markets, including the US, Canada, Europe, and Latin America. Services include:

-- Portfolio planning

-- New product planning

-- Launch excellence

-- Growth maximization

-- Life cycle extension

-- Capability enhancement

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industries. The firm's clients include most of the world's top 20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function, including Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, and Atlanta, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com .

CONTACT:

James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference
2. Campbell Alliance Launches New Practice Area Focused on Trade and Distribution
3. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
4. Campbell Alliance Named Best Place to Work by Triangle Business Journal
5. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
6. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
7. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
8. Workforce Alliance Concludes Three-Year Biotech Training Program
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
11. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):